Spermidine
CAS 124-20-9
Spermidine (CAS 124-20-9) is a Phase 3 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 12212.8 nM | 18 | - |
| - | Ki | 5887.8125 nM | 16 | - |
| - | IC50 | 80734 nM | 15 | - |
| - | AC50 | 22106.015 nM | 2 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| K ir 2.1 Kcnj2 |
Antagonist | 8.100000381469727 pKd | 7748552 |
| K ir 2.3 KCNJ4 |
Antagonist | - | 7969496 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Spermidine used for in pharmaceutical contexts?
Spermidine (CAS 124-20-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Spermidine?
No adverse-event association or SIDER side-effect rows are rendered for Spermidine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Spermidine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Spermidine with EU status "permitted".
What clinical phase is Spermidine in?
Spermidine is rendered with ChEMBL max phase 3.